Loss of function mutations in the gene PARK2, which encodes the protein parkin, cause autosomal recessive juvenile parkinsonism, a neurodegenerative disease characterized by degeneration of the dopaminergic neurons localized in the substantia nigra pars compacta. No therapy is effective in slowing disease progression mostly because the pathogenesis of the disease is yet to be understood. From accruing evidence suggesting that the protein parkin directly regulates synapses it can be hypothesized that PARK2 gene mutations lead to early synaptic damage that results in dopaminergic neuron loss over time. We review evidence that supports the role of parkin in modulating excitatory and dopaminergic synapse functions. We also discuss how these findings underpin the concept that autosomal recessive juvenile parkinsonism can be primarily a synaptopathy. Investigation into the molecular interactions between parkin and synaptic proteins may yield novel targets for pharmacologic interventions. Keywords: parkin; Parkinson's disease; synapse; dopamine; glutamate Abbreviations: AMPAR = -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; KAR = kainic acid receptor; NMDAR = N-methyl-D-aspartate receptor; PDZ = postsynaptic density-95, disc large, zona occludens; PSD = postsynaptic density; SNc = substantia nigra pars compacta
Introduction
Parkin (encoded by PARK2) is a ubiquitin-ligase enzyme expressed in the CNS and in peripheral tissues (Sunada et al., 1998; Picchio et al., 2004; Serdaroglu et al., 2005; Fujiwara et al., 2008; Kasap et al., 2009; Auburger et al., 2012) . At the intracellular level, it catalyses the transfer of ubiquitin from ubiquitin-carrier enzymes to protein substrates and regulates their trafficking and turnover (Cookson, 2003; Houlden and Singleton, 2012; Zhang et al., 2015) . Numerous substrates for parkin have been identified, indicating that it is a multifunctional protein involved in many intracellular processes, including the control of mitochondrial integrity and the regulation of apoptosis and transcription (Scarffe et al., 2014; Charan and LaVoie, 2015) . By ubiquitinating these proteins in various tissues, wild-type parkin may modulate cardiac health (Piquereau et al., 2013) , the risk of cancer (Veeriah et al., 2009; Hu et al., 2016) and disorders such as Alzheimer's disease (Burns et al., 2009) , autism (Glessner et al., 2009) , multiple sclerosis (Witte et al., 2009) , leprosy (Mira et al., 2004) , and inclusion body myositis (Rosen et al., 2006) . Overall, parkin physiologically regulates a variety of cellular processes in neuronal and non-neuronal cells (Charan and LaVoie, 2015) .
Notwithstanding this multiplicity of effects, in humans, loss of function mutations in the PARK2 gene mainly cause early and severe degeneration of dopaminergic neurons of the substantia nigra pars compacta (SNc) (Poulopoulos et al., 2012) . This evidence suggests that, among the many cellular processes regulated by parkin, some are crucial to SNc dopaminergic neuron function and survival. Studies conducted over the last 15 years point to an important role of parkin in modulating neurotransmission of afferent and efferent connections of SNc dopaminergic neurons. Although the exact topology of the synaptic connections of SNc neurons in humans is only partially understood, what is known is that these neurons provide massive innervation of the striatum (Gauthier et al., 1999; Prensa and Parent, 2001; Prensa et al., 2009) , with a single dopaminergic neuron forming over 300 000 synaptic connections through highly branched striatal axons (Arbuthnott and Wickens, 2007; Matsuda et al., 2009) . The afferent connections to SNc dopaminergic neurons mainly consist of GABAergic input from the neostriatum, the globus pallidus, and the substantia nigra pars reticulata (Lee and Tepper, 2009 ) and glutamatergic inputs derived from various brain regions, including the subthalamic and peduncolopontine nuclei, as well as the cortex (Yetnikoff et al., 2014) .
We review evidence that supports the role of parkin in modulating synapse functions. Collectively, these findings highlight that PARK2 gene mutations found in patients with autosomal recessive juvenile parkinsonism (ARJP) may cause dysregulation of the glutamatergic and dopaminergic synapses that culminates in dopaminergic neuron dysfunction and death.
Parkin localizes to presynaptic and postsynaptic terminals
Parkin is a cytosolic protein diffusely distributed in neuronal axons, soma, and dendrites (Helton et al., 2008) . Preliminary investigations disclosed that parkin is localized on synaptic vesicles and displays a distribution pattern similar to that of synapsin I (antibody M74, Supplementary Table 1) (Kubo et al., 2001) , a protein that associates with the cytoplasmic surface of synaptic vesicles (Huttner et al., 1983 ). An immunoelectron microscopy study, performed with the ASP5p antibody, not yet validated using tissues from parkin-knockout mice, showed that parkin is not localized within the vesicles but rather in direct juxtaposition to their membranes (Supplementary  Table 1 ) (Mouatt-Prigent et al., 2004) . This study showed that parkin also localizes at the postsynaptic density (PSD) (antibody ASP5p). Consistently, differential fractioning of rat brain lysates revealed that parkin was enriched in the fraction containing PSD-95 (antibody ASP5p) (Fallon et al., 2002) , the prototypic PSD marker (Sheng and Kim, 2011 ). An immunoelectron microscopy study also showed that the parkin staining intensity was higher in the postsynaptic than in the presynaptic elements (antibody ASP5p).
Taken together, although evidence for the specificity of parkin antibodies in immunohistochemistry experiments is limited, these results show that parkin localizes to presynaptic terminals, where it associates with synaptic vesicles, and at postsynaptic terminals, where it associates with PSDs. These subcellular localization data are consistent with the hypothesis that parkin regulates synaptic functions.
The role of parkin at the dopaminergic synapse: can parkin modulate dopamine release or reuptake?
The localization of parkin at presynapses and its association with the cytoplasmic surface of the synaptic vesicle raises the possibility that it ubiquitinates proteins that regulate synaptic vesicle release or recycling. Wild-type parkin has been found to: interact with, ubiquitinate, and regulate the turnover of CDCrel-1, a protein that associates with synaptic vesicles and regulates their dynamics. Parkin mutations increased the CDCrel-1 level and thus inhibited neurotransmitter release (Zhang et al., 2000) . Parkin also ubiquitinates synphilin-1, a synaptic vesicle-binding protein whose physiological function is currently unknown (Chung et al., 2001) , and binds to synaptotagmin XI, a presynaptic protein involved in synaptic vesicle formation and docking (Huynh et al., 2003) . Evidence that parkin interacts with proteins involved in synaptic vesicle release suggests that presynaptic parkin may regulate dopamine release. This topic was investigated in parkin-knockout mouse models. Increased spontaneous dopamine release from nigral neurons was found in parkin-knockout mice aged 8-9 months (Goldberg et al., 2003) . Decreased evoked dopamine release was found in 3-9 month-old parkin-knockout mice (Oyama et al., 2010) . Dopamine levels in the striatum of 22-month-old wild-type and parkin-knockout mice were reported to be indistinguishable (Perez and Palmiter, 2005 ). Yet, dopamine overflow in striatal slices from 6-8-week-old mice was found to be equal between wild-type and parkin-knockout mice (Sanchez et al., 2014) . Although these discrepancies may stem from different experimental conditions, and/or from in vivo age-dependent compensatory mechanisms, the bulk of the evidence does not support the idea that axonal dopamine release is grossly impaired in parkin-knockout mice. However, it is worth remembering that parkin-knockout mice do not display dopaminergic neuron degeneration and motor impairment: hence, these mouse models do not recapitulate the signs central to autosomal recessive juvenile parkinsonism (Perez and Palmiter, 2005) . The underlying reasons are unknown: parkin loss may be compensated by redundant E3 ubiquitin-protein ligases or parkin functions may differ between rodent and human neurons. Thus, definitive evidence for the role of parkin in controlling dopamine release in human subjects needs to be investigated in human models.
Dopamine release was measured in in vitro dopaminergic neurons derived from human-induced pluripotent stem cells of two PARK2-mutated patients. Spontaneous dopamine release was higher in autosomal recessive juvenile parkinsonism than in control neurons (Jiang et al., 2012) and overexpression of wild-type parkin, but not its mutant T240R, reduced spontaneous dopamine release in autosomal recessive juvenile parkinsonism neurons, thus confirming that the increase in dopamine release stemmed from a loss of parkin function. The picture emerging from this study is that parkin is involved in modulating dopamine release in human neurons, but further studies are necessary to confirm this hypothesis.
Another pathway by which presynaptic parkin may modulate dopamine levels relies on the binding between parkin and the dopamine transporter (DAT), a neurotransmitter transporter localized on the plasma membrane of dopaminergic neurons responsible for the reuptake of dopamine at synaptic and extrasynaptic sites (Torres et al., 2003) . It has been suggested that parkin binds to and ubiquitinates DAT, enhancing DAT expression on the plasma membrane and increasing dopamine uptake (Jiang et al., 2004) . Coherently, dopamine uptake and DAT-binding sites were found to be decreased in dopaminergic neurons derived from human-induced pluripotent stem cells of two PARK2 patients as compared with control neurons (Jiang et al., 2012) . However, analyses of dopamine reuptake in dopaminergic neurons of parkin-knockout mice reported no change as compared to controls (Sanchez et al., Glossary Dopamine: A monoamine neurotransmitter formed in dopaminergic neurons by the decarboxylation of L-DOPA. Dopamine transporter (DAT, SLC6A3): A membrane-spanning protein that pumps back the neurotransmitter dopamine from the synaptic cleft into the cytosol of dopaminergic neurons. Induced pluripotent stem cells (iPSCs): Pluripotent stem cells that have been created from an adult cell through the introduction of genes that induce the reprogramming to an embryonic state. iPSCs have virtually the same properties as embryonic stem cells, and therefore self-renew and can differentiate into all cell types of the body except for cells in extra-embryonic tissues. Ionotropic glutamatergic receptors: Ligand-gated channels that open as a consequence of glutamate binding. These receptors contain an extracellular domain with the binding site for the transmitter, membrane-spanning domains forming an ion-conducting pore and a cytosolic regulatory domain. There are three major subtypes of ionotropic glutamate receptors named according to the type of synthetic agonists that activate them:
a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR): Most of these receptors control a channel permeable to Na + and K + and mediate fast synaptic transmission in the CNS. Miniature excitatory/inhibitory postsynaptic currents: Currents generated by the flow of ions through the open ion channels in a postsynaptic cell following the spontaneous release of neurotransmitters by the presynaptic terminal. They can be recorded using the patch clamp technique. For an excitatory synapse, the binding of neurotransmitters induces the opening of cationic channels that results in a depolarization of the membrane (excitatory postsynaptic currents). For an inhibitory synapse, the binding of neurotransmitters induces the opening of chloride channels resulting in hyperpolarization of the membrane (inhibitory post synaptic currents). PDZ domains: Three repeated regions important for protein-protein interactions. The PDZ domains bind to specific sequences at the extreme carboxy terminus of a number of cellular proteins. They are named PDZ after the three proteins in which they were first identified: PSD-95, the DLG tumour suppressor protein in Drosophila, and a protein termed ZO-1. Postsynaptic density (PSD): An electron-dense structure composed of both membranous and cytoplasmic proteins localized at the postsynaptic membrane of excitatory synapses. Secretory vesicles: A vesicle that mediates the vesicular transport of cargo-e.g. hormones or neurotransmitters-from an organelle to specific sites at the cell membrane, where it docks and fuses to release its content. Substantia nigra pars compacta (SNc): One of the two regions that form the substantia nigra, one of the principal structures of the basal ganglia. The pars compacta contains dopaminergic cells that produce the dark pigment melanin (hence, its dark appearance), synthesize dopamine and project heavily to the striatum and to the other nuclei of the basal ganglia that are involved in mediating movement and motor coordination. Synaptic vesicles: A small secretory vesicle that contains a neurotransmitter, is found inside an axon near the presynaptic membrane, and releases its contents into the synaptic cleft after fusing with the membrane. Trans-Golgi network: A network of stacked membranous vesicles, present in most living cells, that stores and modifies proteins and other macromolecules and transports them within the cell or excretes them from the cell.
2014). These discrepancies may depend on species-dependent parkin function. Taken together, although parkin localizes at the presynapse and preliminary evidence supports the hypothesis that, in human cells, parkin modulates dopamine release and uptake, definitive answers should come from further studies in human models.
The role of parkin at the excitatory synapse: parkin interacts with and ubiquitinates proteins of the postsynaptic densities
The postsynaptic compartment detects the neurotransmitters released from the presynaptic terminal and transduces this signal into electrical and biochemical changes in the postsynaptic cell. In excitatory neurons, the postsynaptic compartment includes the PSD, whose spatial organization is orchestrated by scaffold proteins containing protein-protein interaction modules of 80-90 amino acids, termed postsynaptic density-95, disc large, zona occludens (PDZ) domains (Ye and Zhang, 2013) . The extreme C-terminus of parkin contains a potential PDZ binding motif (Fallon et al., 2002) . This evidence led to the hypothesis that parkin can interact with and/or ubiquitinate PSD proteins, modulating their localization and turnover. Indeed, parkin was found to interact with PSD-95 (Fallon et al., 2002) , which is the best characterized PSD scaffold protein of the excitatory synapses. PSD-95 is involved in anchoring synaptic proteins, including N-methyl-D-aspartate receptors (NMDAR), -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and kainate (AMPA/KAR) receptors, and K + channels (Sheng and Kim, 2011) , modulating their levels at the cell surface, and linking these postsynaptic receptors with their downstream signalling proteins. Because of the key role that PSD-95 plays in modulating membrane receptor levels and functions, the interaction between parkin and PSD-95 suggests that parkin regulates the trafficking, anchoring, and clustering of membrane receptors. Parkin was also found to interact with the synaptic scaffolding molecule CASK (Ca 2 + /CaM-associated serine kinase) (Fallon et al., 2002) , which plays a key role in maintaining the morphology of dendritic spines (Hsueh, 2009) .
Besides these parkin interactors, several other substrates of parkin ubiquitination have been identified within the PSD. Parkin mono-ubiquitinates PICK1, a synaptic scaffold protein that controls the trafficking of numerous neurotransmitter receptors, transporters, ion channels, and enzymes (Joch et al., 2007) . This mono-ubiquitination appears to regulate the effects of PICK1 on the acid-sensing ion channel ASIC2a. Given that ASIC channels contribute to excitotoxicity, it has been posited that loss of parkin may enhance ASIC activity and thereby promote neurodegeneration (Joch et al., 2007) .
To further investigate the role of parkin at the excitatory synapse, we completed a study to determine whether parkin interacts with ionotropic glutamate receptors. We found that parkin interacts with and ubiquitinates the GluK2 subunits of KAR, and thus regulates KAR currents (Maraschi et al., 2014) . The observation that parkin affects somatodendritic KAR currents is consistent with the idea that parkin-GluK2 interaction takes place at postsynaptic sites. As parkin is localized in axons as well, we cannot exclude the possibility that it also regulates presynaptic GluK2-containing KARs, which are involved in facilitating synaptic transmission.
A more recent study on neurotransmitter receptor levels in parkin-knockout mice confirmed the upregulation of KAR densities in numerous cortical areas of parkin-knockout mice. It was also found that NMDAR levels were increased and AMPAR densities were decreased in different brain regions of parkin-knockout mice (Cremer et al., 2015) . The alterations of three different glutamate receptor types underlines the potential relevance of the glutamatergic system in the pathogenesis of PARK2-related Parkinson's disease. Overall, these findings, mainly obtained on cortical or hippocampal preparations, indicate that parkin interacts with and ubiquitinates proteins located at the excitatory synapse both pre-and postsynaptically ( Fig. 1 and Table 1 ). This evidence suggests that parkin orchestrates a general as yet uncharacterized remodelling of synaptic function.
Parkin modulates excitatory synaptic transmission: the excitotoxicity hypothesis
SNc neurons receive glutamatergic inputs from various brain areas, including the cortex, pedunculopontine nuclei, superior colliculus, thalamus, and subthalamic nucleus (Yetnikoff et al., 2014) . While these glutamatergic inputs are essential for basal ganglia physiology, excessively high levels of extracellular glutamate can lead to hyperactivation of ionotropic glutamatergic receptors localized on the dopaminergic neuron membrane and trigger a cascade of intracellular events that promote dopaminergic neuron death. The ensemble of these glutamate-triggered events, termed excitotoxicity, has long been hypothesized to play a key role in Parkinson's disease pathophysiology (Mehta et al., 2013; Ambrosi et al., 2014) . In addition to causing primary damage, excitotoxicity may also contribute to Parkinson's disease progression, since dopamine deficiency causes the subthalamic nucleus to display a continuous abnormal 'bursting' mode of activity (Lozano et al., 2002) that releases high amounts of glutamate in the SNc, which can further exacerbate excitotoxic injury (Olanow and Tatton, 1999; Schapira and Jenner, 2011) . Given the role parkin may play in modulating excitatory synapse functions, the excitotoxicity hypothesis, initially formulated to explain the aetiology of sporadic Parkinson's disease, fits perfectly with the known causes of autosomal recessive juvenile parkinsonism. Loss of parkin function may result in primary excitotoxic damage through the upregulation of glutamate receptors. This hypothesis is supported by experimental evidence. The postsynaptic expression of autosomal recessive juvenile parkinsonism parkin variants results in pruning of excitatory synapses and an increase in the amplitudes of miniature excitatory postsynaptic currents (Helton et al., 2008) . As such currents are the postsynaptic response to the release of a quantum of neurotransmitter from a single synaptic vesicle (Del Castillo and Katz, 1954) , glutamatergic neurotransmission is increased in autosomal recessive juvenile parkinsonism neurons. Autosomal recessive juvenile parkinsonism neurons are also more vulnerable than control neurons to excitotoxic stimuli (Helton et al., 2008) . The observed increase in neurotransmission is consistent with higher density/conductance of glutamatergic postsynaptic receptors at individual synapses and suggests that a loss of parkin function increases the density/conductance of postsynaptic receptors.
The postsynaptic currents at the excitatory synapses of dopaminergic neurons consist of two components: a rapid component mediated by AMPAR/KAR and a slower component mediated by NMDAR (Mereu et al., 1991) . Evidence suggests that, among ionotropic glutamate receptors potentially involved in excitotoxicity, parkin directly regulates AMPAR/KAR. Interestingly, upon silencing of endogenous parkin, dopaminergic neurons are more vulnerable than control neurons to treatment with kainate, an AMPAR/KAR agonist, and this effect is rescued by overexpression of wild-type parkin (Staropoli et al., 2003) . In line with these observations, loss of parkin function was demonstrated to potentiate KAR currents and increase KAR-dependent excitotoxicity (Maraschi et al., 2014) . Overall, accruing evidence suggests that parkin modulates the density/conductance of glutamate postsynaptic receptors and that loss of parkin upregulates excitatory currents, leading to dopaminergic neuron death by excitotoxicity. Moreover, because dopamine deficiency induces subthalamic nucleus hyperactivity that, in turn, increases glutamate release in the SNc (Rodriguez et al., 1998; Olanow and Tatton, 1999; Lozano et al., 2002) , we can hypothesize that parkin loss of function in autosomal recessive juvenile parkinsonism patients may cause primary excitotoxic damage that precedes the excitotoxic damage due to overactivity of the subthalamic nucleus glutamatergic neurons.
Excitatory synapse abnormalities may also underlie dystonia at the onset of the disease and early development of L-DOPA-induced dyskinesia in PARK2-mutated patients (Ishikawa and Tsuji, 1996; Schrag and Schott, 2006) . These hyperkinetic symptoms are thought to result from impaired synaptic plasticity at the excitatory cortical striatal synapses and are known to involve glutamatergic hyperactivity (Gardoni and Di Luca, 2015) .
Hence, glutamatergic hyperactivity in autosomal recessive juvenile parkinsonism may play a dual role: it can promote excitotoxic events that contribute to the neurodegenerative process and it can contribute to dystonia at the onset and early development of levodopa-induced dyskinesias.
The synaptopathy hypothesis in PARK2 disease versus idiopathic Parkinson's disease: similarities and differences Early synaptic failure has long been suggested to be a major pathogenic determinant in idiopathic Parkinson's disease (Calo et al., 2016; Schirinzi et al., 2016) . To assess the difference in the functionality of the presynaptic dopaminergic nerve terminal between healthy subjects, idiopathic Parkinson's disease, and PARK2-mutated patients, in vivo studies were performed with PET. The uptake of the radiotracer 18 F-DOPA was used to measure changes in aromatic L-amino decarboxylase activity, which is dependent on the availability of striatal dopaminergic nerve terminals. As expected, a significant reduction in 18 F-DOPA uptake was found in both idiopathic Parkinson's disease and PARK2 patients. However, while idiopathic patients showed marked asymmetry of 18 F-DOPA uptake, PARK2-mutated patients displayed a reduction that affected both hemispheres similarly (Hilker et al., 2001; Ribeiro et al., 2009) and more stably over time (Khan et al., 2002; Pavese et al., 2009) . In addition, the reduction in 18 F-DOPA uptake was proportional to disease severity in patients with idiopathic Parkinson's disease but not in PARK2 patients (Thobois et al., 2003; Scherfler et al., 2004) . These results suggest that, despite its slow clinical progression, PARK2 disease is associated with earlier, more severe and widespread presynaptic dopaminergic deficits.
A comparison of the presynaptic deficit observed in PARK2 disease and idiopathic Parkinson's disease at the molecular level highlights one important difference: the early synaptic impairment in idiopathic Parkinson's disease is thought to be caused by the presence, at the striatal dopaminergic terminals, of Lewy bodies whose major component is an aggregated form of the presynaptic protein -synuclein (Calo et al., 2016) . However, Lewy bodies are absent or rare in the brain tissues of PARK2 patients Doherty and Hardy, 2013) . This neuropathological evidence suggests that synaptic impairment in PARK2 patients and in idiopathic Parkinson's disease may stem from different causes and supports the hypothesis that parkin does have a specific, yet not fully clarified, action at the synapse.
Conclusions
Accruing evidence supports the involvement of parkin in directly regulating synaptic function. Data obtained on cortical or hippocampal preparations of PARK2 models bring into light dysfunction of excitatory synapses. Data obtained on dopamine release and uptake in PARK2 models suggest dysfunctioning of dopaminergic synapses. Preliminary evidence also exists for the dysregulation of GABA receptor density (Cremer et al., 2015) . In this context, it is conceivable that the earliest event in PARK2 mutated patients may be synapse impairment. This hypothesis adds to and integrates other hypotheses for autosomal recessive juvenile parkinsonism pathogenesis, such as abnormal mitophagy, mitochondrial fusion and fission, proteostasis, apoptosis, and transcription (Seirafi et al., 2015; Zhang et al., 2015) . Based on hypotheses for hyperactivation of the excitatory synapse, glutamatergic antagonists have been tested in idiopathic Parkinson's disease patients. The results from these clinical trials suggest that, while these agents can have positive effects on the dyskinesias and motor fluctuations associated with the chronic use of L-DOPA, the clinical outcomes are still insufficient to consider them as diseasemodifying drugs (Jankovic and Hunter, 2002; Braz et al., 2004) . However, one difficulty in evaluating the activity of these drugs can be ascribed to the fact that they have been tested in a mixed population of Parkinson's disease patients.
By stratifying patients with Parkinson's disease according to their genetic risk factors and utilizing tools for preclinical detection of pathophysiologic processes, we might be able to design molecularly tailored interventions. When caring for PARK2 mutated patients, further research into identifying parkin interactors or parkin ubiquitination targets among synaptic proteins may yield specific glutamatergic antagonists that can counteract the synaptopathy induced by PARK2 mutations.
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